Amgen Inc. (AMGN)
The Zacks Analyst Blog Eli Lilly, Novo Nordisk's Amgen and Viking Therapeutics
Eli Lilly, Novo Nordisk's Amgen and Viking Therapeutics are included in this Analyst Blog.
2 No-Brainer Dividend Stocks With Yields Over 3% to Buy in 2025 and Hold for a Decade or Longer
Whether you're looking for a way to beat the benchmark S&P 500 index or you just want a steady flow of passive income, dividend-paying stocks are a great way to achieve your investment goals.
Johnson & Johnson Is A Better Dividend Stock Than Amgen In Our View
Recent market concerns have pressured the stock prices of both Johnson & Johnson and Amgen Inc. In times of uncertainties, I go back to timeless insights like those offered by Peter Lync on dividend stocks. These insights led me to rate JNJ as a strong buy, a well-rounded package featuring yield, dividend consistency/safety, valuation, and effective inventory management.
Healthy Returns: Wall Street mulls over Amgen's weight loss drug data
Wall Street is chewing over data on Amgen's weight loss injection, MariTde. Meanwhile, GE HealthCare will acquire a Japanese drug company.
Amgen to invest $1 bln in North Carolina manufacturing site
U.S. drugmaker Amgen said on Thursday it will invest $1 billion towards a second drug substance manufacturing facility in North Carolina.
Is Amgen Still a Top Dividend Stock?
The relationship between interest rates and dividend stocks tends to follow a predictable pattern. When the Federal Reserve signals a shift toward monetary easing, investors often rotate toward stable, high-yielding equities that can provide both income and potential appreciation.
Amgen Inc. (AMGN) Annual Evercore ISI HealthCONx Healthcare Conference (Transcript)
Amgen Inc. (NASDAQ:AMGN ) Annual Evercore ISI HealthCONx Healthcare Conference December 4, 2024 10:00 AM ET Company Participants Peter Griffith - Executive Vice President and Chief Financial Officer James Bradner - Executive Vice President, Research and Development, and Chief Scientific Officer Susan Sweeney - Executive Vice President, Obesity and Related Conditions Justin Claeys - Vice President, Investor Relations Conference Call Participants Umer Raffat - Evercore ISI Umer Raffat Excellent. Hello, everyone.
Amgen Stock Falls 12% in a Month: Should You Buy the Dip?
AMGN's reasonable valuation, an interesting pipeline and continued top-line growth are good enough reasons to stay invested in the stock for now.
Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance
The battle for the multibillion-dollar obesity market just got fiercer. Amgen Inc's AMGN new drug candidate, MariTide, reported promising results, helping patients shed around 20% of their body weight.
This Stock Just Dropped by 12% in 1 Day: Should You Buy the Dip?
The biotech industry can be volatile even for relatively large companies. Amgen (AMGN 1.00%), one of the more prominent names in the game, just reminded us all of that fact.
Amgen removed from US Conviction List at Goldman Sachs
Goldman Sachs analysts removed Amgen from the firm's US Conviction List as part of its monthly update.
Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy?
The market didn't appreciate Amgen's (AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more than 12% at one point on Nov. 26 from the previous day's close, though they recovered to close just 4.7% down for the day.
